---
title: A study to improve the delivery of AB-1005 gene therapy into the brain
euct_id: 2025-522441-21-00
phase: Phase 4
status: Not yet recruiting
sponsor: Askbio Inc.
canonical_url: "https://parkinsonspathways.com/trials/eu/2025-522441-21-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2025-522441-21-00"
ctis_last_updated: "2026-04-04T03:34:27.364372372"
source: EU Clinical Trials Information System (CTIS)
---
# A study to improve the delivery of AB-1005 gene therapy into the brain

**EU CT Number:** [2025-522441-21-00](https://euclinicaltrials.eu/ctis-public/view/2025-522441-21-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Not yet recruiting
- **Sponsor:** Askbio Inc.
- **Start Date:** 2026-05-01
- **Completion Date:** 2028-12-31
- **Conditions:** Parkinson's Disease
- **Interventions:** AAV2-GDNF, ProHance, 279,3 mg/ml (0,5 mmol/ml), roztwór do wstrzykiwan

## Member States

Trial is authorized in 1 member state: Poland.

## Sites (3)

- Copernicus Podmiot Leczniczy Sp. z o.o., Gdansk, Poland
- Specjalistyczna Praktyka Lekarska Prof. Grzegorz Opala, Katowice, Poland
- Mazowiecki Szpital Brodnowski Sp. z o.o., Warsaw, Poland

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's Disease
Age groups: elderly 65+, adults 18-64
Sex: male, female
Includes a vulnerable population.
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2025-522441-21-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2025-522441-21-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2025-522441-21-00*